1,680 reports of this reaction
2.9% of all MEDROXYPROGESTERONE ACETATE reports
#3 most reported adverse reaction
MENINGIOMA is the #3 most commonly reported adverse reaction for MEDROXYPROGESTERONE ACETATE, manufactured by Pharmacia & Upjohn Company LLC. There are 1,680 FDA adverse event reports linking MEDROXYPROGESTERONE ACETATE to MENINGIOMA. This represents approximately 2.9% of all 57,188 adverse event reports for this drug.
Patients taking MEDROXYPROGESTERONE ACETATE who experience meningioma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MENINGIOMA is a less commonly reported adverse event for MEDROXYPROGESTERONE ACETATE, but still significant enough to appear in the safety profile.
In addition to meningioma, the following adverse reactions have been reported for MEDROXYPROGESTERONE ACETATE:
MENINGIOMA has been reported as an adverse event in 1,680 FDA reports for MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MENINGIOMA accounts for approximately 2.9% of all adverse event reports for MEDROXYPROGESTERONE ACETATE, making it one of the most commonly reported side effect.
If you experience meningioma while taking MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.